Bristol-Myers Squibb Company (NYSE: BMY) — Company Overview, News & Financial Data
Bristol-Myers Squibb is a global biopharmaceutical company focused on innovative medicines for serious diseases, including oncology and
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is a global biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, and marketing of prescription human medicines. The company focuses its research and commercial development across primary therapeutic areas including oncology, hematology, cardiovascular diseases, immunology, and neuroscience. Its clinical development pipeline contains dozens of investigative compounds across multiple disease areas. Operating worldwide, the organization serves patients and medical healthcare providers through proprietary prescription treatments, clinical trials, and commercial distribution networks across North America, Europe, Asia-Pacific, and Latin America.
Snapshot
Operations
Products and/or services of Bristol-Myers Squibb Company
- Oncology: Focuses on research, clinical trials, and global development of targeted cancer therapies and immuno-oncology treatments designed to combat solid tumors and advanced malignancies for healthcare providers and patients worldwide.
- Hematology: Develops and commercializes therapies targeting serious blood disorders and hematologic malignancies, providing treatment solutions and clinical options for diseases such as relapsed or refractory multiple myeloma, systemic light-chain amyloidosis, and related blood conditions.
- Cardiovascular: Researches and commercializes cardiovascular medicines designed to treat complex heart conditions, including symptomatic obstructive hypertrophic cardiomyopathy and thromboembolic diseases, providing therapeutic options for adult and pediatric cardiac patients across international markets.
- Immunology: Researches and manufactures targeted therapies for immune-mediated inflammatory conditions across dermatology, gastroenterology, rheumatology, and pulmonology, providing treatments for autoimmune disorders such as moderate-to-severe plaque psoriasis and psoriatic arthritis.
- Neuroscience: Focuses on developing disease-modifying and symptomatic treatments for neurological and psychiatric diseases, advancing clinical trials, research platforms, and targeted pharmaceutical assets to address significant unmet clinical needs in neurodegenerative conditions.
- Research and Pipeline Development: Conducts clinical trial orchestration, targeted protein degradation research, and early-stage compound discovery using artificial intelligence and machine learning technologies to advance dozens of active drug candidates through preclinical and clinical phases.
Bristol-Myers Squibb Company executive team
- Christopher S. BoernerCEO & Chairman
- David V. ElkinsExecutive VP & CFO
- Greg MeyersExecutive VP and Chief Digital & Technology Officer
- Adam LenkowskyExecutive VP & Chief Commercialization Officer
- Cristian MassacesiExecutive VP, Chief Medical Officer & Head of Development
- Karin ShanahanExecutive VP, Chief Supply Chain & Operations Officer
- Charles E. TrianoSVP & Head of Investor Relations
- Cari GallmanExecutive VP, General Counsel & Chief Policy Officer
- Ahn Amanda PooleExecutive VP & Chief People Officer
- Joseph J. Eiden Jr.Head of Medical Affairs
Latest news about Bristol-Myers Squibb Company
Bristol Myers lung cancer trial shows 11.1-month PFS
United StatesBristol Myers shares fall 2.4% after fatal trial event
United StatesBristol Myers Squibb RYZ101 trial meets Phase 3 goal
United StatesBristol Myers Squibb drug meets IPF trial endpoint
United StatesBristol Myers Squibb ZENBEXUS cuts progression risk 51%
United StatesBristol Myers Squibb reports Sotyktu trial results
United States
Dividend history
Dividends per share paid by Bristol-Myers Squibb Company, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2026(to date) | — | — | — | $2.5200 |
| FY2025 | — | — | — | $2.4800 |
| FY2024 | — | — | — | $2.4000 |
| FY2023 | — | — | — | $2.2800 |
| FY2022 | — | — | — | $2.1600 |
Key financials
Reported results for Bristol-Myers Squibb Company, in USD.
- Market cap
- 125.7B
- Revenue (TTM)
- 49.2B
- P/E ratio
- 13.6
- EPS (diluted, TTM)
- 4.5
- Dividend yield
- 4.1%
- Profit margin
- 18.9%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 48.2B | 13.7B | 7.1B | |
| 48.3B | 5.9B | -8.9B | |
| 45B | 8.2B | 8B | |
| 46.2B | 9.1B | 6.3B |